Roche (RHHBY.US) has received acceptance from the CDE for its marketing application for faricimab injection, intended for the treatment of uveitic macular edema.

On September 3, the CDE official website announced that Roche's (RHHBY.US) application for the marketing of vamikibart injection has been accepted for review, aimed at treating uveitic macular edema (UME). Previously, this application had been included in the CDE's priority review and approval process. Source: CDE official website Vamikibart is an investigational IL-6 monoclonal antibody administered via intravitreal injection. IL-6 is a key cytokine in inflammatory responses and can promote vascular leakage, retinal thickening, and decreased visual function in intraocular inflammatory conditions such as uveitis and macular edema. Vamikibart can effectively inhibit the IL-6 signaling pathway, blocking these pathological processes at their source. Vamikibart was initially developed by Eleven Biotherapeutics. In June 2016, Roche acquired the global development and commercialization rights to this product.